Tejnaksh Health.

Why is Tejnaksh Healthcare Ltd falling/rising?

As of 13-Aug, Tejnaksh Healthcare Ltd's stock price is at 14.20, reflecting a decline of 1.25% after a trend reversal. Despite a 7.90% increase over the past week, the stock has underperformed over longer periods, indicating overall weakness and a bearish trend.

As of 13-Aug, Tejnaksh Healthcare Ltd's stock price is falling, currently at 14.20, which reflects a decrease of 0.18 or 1.25%. This decline follows a trend reversal after three consecutive days of gains, indicating a shift in market sentiment. The stock has underperformed its sector today, contributing to the downward movement.<BR><BR>In terms of performance, while the stock experienced a notable increase of 7.90% over the past week, it has struggled over longer periods, showing a decline of 2.94% in the last month and a significant drop of 24.87% over the past year. Additionally, the stock's year-to-date performance is down by 5.27%, which is better than the Sensex's decline of 8.38% but still indicates overall weakness.<BR><BR>Investor participation appears to be decreasing, as evidenced by a drop in delivery volume by 0.73% against the five-day average. Furthermore, while the stock's price is higher than its 5-day and 20-day moving averages, it remains below the 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the longer term. Overall, these factors contribute to the current decline in Tejnaksh Healthcare Ltd's stock price.

Should I buy, sell or hold Tejnaksh Healthcare Ltd?

Which are the latest news on Tejnaksh Health.?

Who are in the management team of Tejnaksh Health.?

The management team of Tejnaksh Health includes Chairman Ashish Vishwas Rawandale, Non-Executive Directors Preeti Ashish Rawandale and Sanjay Bhikajirao Khatale, and Independent Non-Executive Directors Kiran Madhavrao Pawar, Vikramsinh Satish Khatal Patil, and Suhas Vasantrao Thorat. This diverse board offers a variety of perspectives and expertise.

The management team of Tejnaksh Health includes the following individuals:<BR><BR>1. **Ashish Vishwas Rawandale** - Chairman / Executive Director<BR>2. **Preeti Ashish Rawandale** - Non-Executive & Non-Independent Director<BR>3. **Kiran Madhavrao Pawar** - Independent Non-Executive Director<BR>4. **Vikramsinh Satish Khatal Patil** - Independent Non-Executive Director<BR>5. **Sanjay Bhikajirao Khatale** - Non-Executive & Non-Independent Director<BR>6. **Suhas Vasantrao Thorat** - Independent Non-Executive Director<BR><BR>This diverse board brings a range of perspectives and expertise to the company.

How big is Tejnaksh Health.?

As of 10th June, Tejnaksh Healthcare Ltd has a market capitalization of 29.00 Cr, with recent net sales of 10.79 Cr and a net profit of 1.22 Cr. The balance sheet for March 2025 shows shareholder's funds of 25.91 Cr and total assets of 30.31 Cr.

As of 10th June, Tejnaksh Healthcare Ltd has a market capitalization of 29.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Tejnaksh Healthcare Ltd reported Net Sales of 10.79 Cr and a Net Profit of 1.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 25.91 Cr and Total Assets of 30.31 Cr.

Who are the peers of the Tejnaksh Health.?

Tejnaksh Health's peers include Deccan Healthcar, GKB Ophthalmics, Centenial Surgic, Chennai Meena, Transgene Biotek, Adeshwar Meditex, Family Care, Vanta Bioscience, and Galaxy Medicare. In terms of performance, Chennai Meena leads with a 1-year return of 17.93%, while Tejnaksh Health has a return of -34.31%.

Peers: The peers of Tejnaksh Health. are Deccan Healthcar, GKB Ophthalmics, Centenial Surgic, Chennai Meena, Transgene Biotek, Adeshwar Meditex, Family Care, Vanta Bioscience, and Galaxy Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Average management risk is found at Galaxy Medicare, and the rest have Below Average management risk. Good growth is noted at Family Care and Deccan Healthcar, while Below Average growth is seen at Tejnaksh Health., GKB Ophthalmics, Adeshwar Meditex, Vanta Bioscience, and the rest. Good capital structure is present at Tejnaksh Health. and Family Care, Average capital structure is found at Centenial Surgic and Adeshwar Meditex, while the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Chennai Meena at 17.93%, while the lowest is Deccan Healthcar at -39.81%. Tejnaksh Health.'s 1-year return is -34.31%, which is better than Deccan Healthcar but worse than Chennai Meena. Additionally, several peers, including GKB Ophthalmics, Centenial Surgic, Adeshwar Meditex, Family Care, and Vanta Bioscience, have negative six-month returns.

What does Tejnaksh Health. do?

Tejnaksh Healthcare Ltd is a micro-cap company based in Mumbai, specializing in urology services through its ISO certified hospital. As of March 2026, it reported net sales of 3 Cr and a market cap of INR 29 Cr.

Overview:<BR>Tejnaksh Healthcare Ltd operates in the healthcare services industry as a micro-cap company, specializing in urology services through its ISO certified hospital.<BR><BR>History:<BR>Tejnaksh Healthcare Ltd was incorporated in Mumbai on 18 February 2008 as a Private Limited Company and transitioned to a Public Limited Company on 10 March 2015. The most recent quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap: INR 29 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 23.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.07<BR>- Return on Equity: 4.49%<BR>- Price to Book: 1.03<BR><BR>Contact Details:<BR>Address: A 601 Floor No 6 Kailash, Business Park Veer SavarkarMar Mumbai Maharashtra : 400079<BR>Email: cs.tejnaksh@gmail.com<BR>Website: http://www.tejnaksh.com

Are Tejnaksh Healthcare Ltd latest results good or bad?

Tejnaksh Healthcare Ltd's latest results show improved operating margins and a sequential profit recovery, but a 20.56% year-on-year decline in net sales raises concerns about its long-term viability. Investors should be cautious due to these ongoing revenue challenges.

Tejnaksh Healthcare Ltd's latest results present a mixed picture. On one hand, the company has shown some improvement in operating margins, which increased to 27.84% from 21.81% year-on-year. This suggests that the company has been able to manage its costs more effectively. Additionally, the consolidated net profit rose by 20% quarter-on-quarter to ₹0.36 crores, indicating a recovery in profitability on a sequential basis.<BR><BR>However, the overall performance is overshadowed by significant challenges. Net sales contracted by 20.56% year-on-year to ₹2.55 crores, marking the third consecutive quarter of year-on-year revenue decline. This persistent drop raises concerns about the company's ability to attract and retain patients, particularly in a competitive healthcare environment. The stock has also reacted negatively to these results, trading down 0.65% and sitting significantly below its 52-week high.<BR><BR>In summary, while there are signs of improved cost management and sequential profit recovery, the ongoing decline in revenue is a serious concern, indicating that the company is facing structural challenges that could impact its long-term viability. Investors should be cautious and monitor future performance closely.

When is the next results date for Tejnaksh Healthcare Ltd?

The next results date for Tejnaksh Healthcare Ltd is 30 May 2026.

The next results date for Tejnaksh Healthcare Ltd is scheduled for 30 May 2026.

How has been the historical performance of Tejnaksh Health.?

Tejnaksh Health's historical performance shows fluctuating net sales and profits, with a decline from Mar'19 to Mar'20, followed by recovery; net sales rose to 12.90 Cr in Mar'25 from 11.73 Cr in Mar'23, but cash flow from operations dropped to 0.00 Cr in Mar'25, indicating challenges despite improved profits.

Answer:<BR>The historical performance of Tejnaksh Health shows a fluctuating trend in net sales and profits over the years, with a notable decline from Mar'19 to Mar'20, followed by a gradual recovery. <BR><BR>Breakdown:<BR>Tejnaksh Health's net sales increased from 11.73 Cr in Mar'23 to 12.90 Cr in Mar'25, reflecting a positive growth trend. However, this is a decrease from the peak of 19.76 Cr in Mar'19. The total operating income also followed a similar pattern, rising to 12.90 Cr in Mar'25 from 11.73 Cr in Mar'23. The company's total expenditure, excluding depreciation, has increased from 8.04 Cr in Mar'23 to 8.82 Cr in Mar'25, indicating rising operational costs. Operating profit (PBDIT) improved to 4.48 Cr in Mar'25 from 4.00 Cr in Mar'23, while profit before tax rose to 3.19 Cr in Mar'25 from 2.51 Cr in Mar'23. The profit after tax also saw an increase, reaching 2.23 Cr in Mar'25 compared to 1.79 Cr in Mar'23. On the balance sheet, total liabilities decreased from 31.23 Cr in Mar'23 to 30.31 Cr in Mar'25, while total assets also slightly declined from 31.23 Cr to 30.31 Cr in the same period. The company's cash flow from operating activities showed a significant drop to 0.00 Cr in Mar'25 from 2.00 Cr in Mar'23, indicating challenges in generating cash from operations. Overall, while Tejnaksh Health has shown some recovery in sales and profits, it faces pressures on cash flow and rising costs.

Who are the top shareholders of the Tejnaksh Health.?

The top shareholder of Tejnaksh Health is Ashish Vishwas Rawandale, holding 38.15%. The highest public shareholder is Sheetal Utkarsh Rawandale at 1.45%, with individual investors owning a total of 23.58%.

The top shareholders of Tejnaksh Health include the promoters, with Ashish Vishwas Rawandale holding the largest share at 38.15%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sheetal Utkarsh Rawandale, who owns 1.45%. Additionally, individual investors collectively hold 23.58% of the company.

Is Tejnaksh Health. overvalued or undervalued?

As of July 30, 2024, Tejnaksh Health is considered very attractive and undervalued with a PE ratio of 19.05, strong growth potential indicated by a PEG ratio of 0.54, and favorable comparisons to peers like Max Healthcare and Apollo Hospitals, despite a challenging year with a stock return of -11.6%.

As of 30 July 2024, the valuation grade for Tejnaksh Health has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a price-to-earnings (PE) ratio of 19.05, an EV to EBITDA ratio of 10.84, and a PEG ratio of 0.54, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Tejnaksh Health stands out favorably; for instance, Max Healthcare is deemed very expensive with a PE ratio of 100.29, while Apollo Hospitals has a PE ratio of 69.03. The company's solid return on capital employed (ROCE) of 12.73% and return on equity (ROE) of 9.15% further reinforce its attractiveness. Despite a challenging year with a stock return of -11.6% compared to the Sensex's 7.62%, the current valuation metrics suggest that Tejnaksh Health presents a compelling investment opportunity.

What is the technical trend for Tejnaksh Health.?

As of June 6, 2025, Tejnaksh Health's trend has shifted to sideways, with mixed indicators showing mild bullish momentum on the weekly MACD and KST, while daily moving averages and Bollinger Bands suggest a consolidation phase without a clear directional bias.

As of 6 June 2025, the technical trend for Tejnaksh Health has changed from mildly bearish to sideways. The current stance is neutral, with a mix of indicators influencing the outlook. The weekly MACD and KST are both mildly bullish, suggesting some positive momentum, while the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a mildly bearish stance on the weekly chart and sideways on the monthly chart. Overall, the lack of strong signals from the RSI and Dow Theory indicates a consolidation phase without a clear directional bias.

What is the bonus history of the Tejnaksh Health.?

Tejnaksh Health's recent bonus history includes a 36:10 bonus issued on April 26, 2018, with a record date of April 28, 2018, and a previous 1:1 bonus issued on March 8, 2017, with a record date of March 9, 2017.

Tejnaksh Health has a notable bonus history. The most recent bonus issue was a 36:10 ratio, which was announced with an ex-date of April 26, 2018, and a record date of April 28, 2018. Prior to that, the company issued a bonus with a 1:1 ratio, which had an ex-date of March 8, 2017, and a record date of March 9, 2017. If you have any more questions about Tejnaksh Health or its financial activities, feel free to ask!

Has Tejnaksh Health. declared dividend?

No Dividend History Available